Literature DB >> 36002650

Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.

Anusorn Kiattanaphon1, Yaovaluk Vipsoongnern2, Duangkamol Kunthalert1, Anchalee Sistayanarain3.   

Abstract

BACKGROUND: The hepatitis C virus (HCV) is a major cause of illness around the world. HCV genotype 3a is the most prevalent genotype in Thailand. Direct-acting antiviral (DAA) drugs are available for treatment, and these drugs target the NS3, NS5A, and NS5b proteins of HCV. However, HCV variants that are resistant to NS3 protease inhibitors have been found during treatment. This resistance can be naturally occurring or in response to treatment. The purpose of this study is to analyze the codon positions of the main mutation of the partial NS3 gene region of HCV genotype 3a.
METHODS: In order to detect mutations and confirm the genotype of HCV genotype 3a, the nucleotide sequencing and amino acid portion of NS3 were analyzed.
RESULTS: Twenty-six samples were successfully sequenced and clustered within two sub-clades defined as 3a-1 and 3a-2. Through amino acid mutation analysis, the variations were detected at codon positions 122 (3.8%), 132 (84.6%), 168 (100%), 170 (92.3%), 174 (100%), and 175 (100%).
CONCLUSIONS: In conclusion, mutations at positions 168, 170, 174, and 175 of the NS3 region are common within the HCV genotype 3a. This information should be useful in the development of effective anti-viral drugs that can successfully treat HCV infection.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Direct-acting antiviral (DAA) agents; Genotype 3a; Hepatitis C Virus (HCV); NS3 gene

Mesh:

Substances:

Year:  2022        PMID: 36002650     DOI: 10.1007/s11033-022-07803-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  32 in total

1.  An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region.

Authors:  Tatsunori Nakano; Gillian M G Lau; Grace M L Lau; Masaya Sugiyama; Masashi Mizokami
Journal:  Liver Int       Date:  2011-12-05       Impact factor: 5.828

Review 2.  Replication of hepatitis C virus.

Authors:  Darius Moradpour; François Penin; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2007-05-08       Impact factor: 60.633

Review 3.  Hematologic side effects of interferon and ribavirin therapy.

Authors:  Kris V Kowdley
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

4.  A shift in the hepatitis C virus genotype dominance in blood donor samples from Thailand.

Authors:  Anchalee Sistayanarain; Duangkamol Kunthalert; Yaovaluk Vipsoongnern
Journal:  Mol Biol Rep       Date:  2010-11-27       Impact factor: 2.316

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

Authors:  Paul Y Kwo; Fred Poordad; Armen Asatryan; Stanley Wang; David L Wyles; Tarek Hassanein; Franco Felizarta; Mark S Sulkowski; Edward Gane; Benedict Maliakkal; J Scott Overcash; Stuart C Gordon; Andrew J Muir; Humberto Aguilar; Kosh Agarwal; Gregory J Dore; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  J Hepatol       Date:  2017-04-13       Impact factor: 25.083

Review 7.  Antivirals against HCV infection: the story thus far.

Authors:  Ahmad Adebayo Irekeola; Engku Nur Syafirah Ear; Nur Amalin Zahirah Mohd Amin; Nazri Mustaffa; Rafidah Hanim Shueb
Journal:  J Infect Dev Ctries       Date:  2022-02-28       Impact factor: 0.968

8.  Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.

Authors:  Ahmad Adebayo Irekeola; Nurul Adila Malek; Yusuf Wada; Nazri Mustaffa; Nur Izat Muhamad; Rafidah Hanim Shueb
Journal:  PLoS One       Date:  2021-05-20       Impact factor: 3.240

9.  Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.

Authors:  Eric Lawitz; Fred Poordad; Julio A Gutierrez; Jennifer T Wells; Carmen E Landaverde; Barbara Evans; Anita Howe; Hsueh-Cheng Huang; Jerry Jing Li; Peggy Hwang; Frank J Dutko; Michael Robertson; Janice Wahl; Eliav Barr; Barbara Haber
Journal:  Hepatology       Date:  2016-12-19       Impact factor: 17.298

10.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.